⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 2, 2026Endocrine Related CancerOpen Access

PRRT for well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Virginia Corbett Garima Gupta Aman Chauhan

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the sequencing of peptide receptor radionuclide therapy (PRRT) to optimize treatment for GEP-NETs.
Reviewed current literature on PRRT and its application in GEP-NET management.
Assessed patient-specific factors for tailoring treatment plans.
Emphasized a multidisciplinary approach in decision-making.
Found that optimized sequencing may lead to improved patient outcomes.
Highlighted the importance of personalized treatment approaches in GEP-NET care.

Implication

This review explores treatment sequencing for GEP-NETs, suggesting a personalized approach to improve outcomes.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Corbett et al. (2026) studied this question.

synapsesocial.com/papers/69a7cd7ed48f933b5eed9e52 https://doi.org/10.1530/erc-25-0495

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Sequencing Choices and Real-World Clinical Management in Advanced Grade 2/3 GEP-NET Treatment: The Emerging Role of PRRT2025 · 2 citations
2Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumoursHuman Clinical Trial · 2026
3Recommendations for selection, treatment, and follow-up in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors: a Delphi consensus from the Galician Multidisciplinary Group on Neuroendocrine and Endocrine Tumors (GGNET)Original Research · 2026
4Whole genome and exome sequencing of pancreatic NET to investigate PRRT responseOriginal Research · 2026 · 1 citations
5Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directionsLate-Phase Clinical Trial · 2026 · 8 citations

More related papers

Treatment of Neuroendocrine Tumours: Approach of GEP-NETS2025
Primary tumor resection prior to peptide receptor radionuclide therapy is associated with improved survival in metastatic gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis2026
An Update on Novel Pharmacotherapies for the Treatment of Neuroendocrine Tumors2025

More from Endocrine Related Cancer

Thyroid Differentiation Score as a Molecular Bridge Between Genotype, Tumor Biology, and Radioiodine Theranostics in Thyroid CancerTue,
Streptozotocin-based chemotherapy in advanced PanNETs: a systematic review and meta-analysisMon,